Navigation Links
Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
Date:2/8/2011

Toronto Faster approval times for generic drugs will get them into consumers' hands quicker, but may not make the price any better, a pricing and marketing researcher has found.

A mathematical model created by Andrew Ching shows that fewer firms enter the marketplace because the chances of getting there first and commanding the best profits are dramatically smaller when drug approval times are shorter. Ching is an associate professor of marketing at the University of Toronto's Rotman School of Management.

Using the drug clonidine, Prof. Ching's model showed the number of firms in the marketplace dropped by 25 percent, from 12 to nine, under a shortened approval time scenario.

"Potentially, for the consumer, the price may not drop as much as you'd hope," said Prof. Ching.

Under the current situation it takes companies an average of more than 20 months to get U.S. Food and Drug Administration (FDA) approval for generic versions of established drugs. That makes approval times uncertain and companies often must go through several rounds of review. Companies also pay several million dollars when they apply for FDA approval. Given these as well as other development costs, firms making it to the marketplace last sometimes experience losses.

The FDA in recent years has talked about reducing its approval times in order to benefit consumers, and has proposed strategies for how it could do so, including spending more money in order to bring on extra staff to do the reviews.

Prof. Ching says his results, which were published in International Economic Review, suggest the FDA should think twice before going that route.

"Even if the government spends a large amount of resources to improve the efficiency of the FDA in approving generic drugs, it does not necessarily achieve the goal of enhancing welfare," Prof. Ching's paper concludes.


'/>"/>

Contact: Ken McGuffin
mcguffin@rotman.utoronto.ca
416-946-3818
University of Toronto, Rotman School of Management
Source:Eurekalert

Page: 1

Related medicine news :

1. Generic drug may improve the effectiveness of cancer nanotherapies
2. Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial
3. SNM applauds FDA advisory committee recommendation for approval of Alzheimers imaging agent
4. FDA Advisers Consider Approval of Genetically Modified Salmon
5. FDA Advisers Weigh Approval of Genetically Modified Salmon
6. FDA Panel Votes Against Approval of Female Viagra
7. Mr. Dad and GreatDad.com Salute Fathers and Families with This Spring's ‘Seal of Approval' Picks
8. US Department of Education Financial Aid Approval
9. Hydroponics Nutrients For Medical Marijuana Gain Government Approval
10. United Nations Approval Rating rises to 60% in New Opinion Poll
11. FDA Warns Cosmetic Doctor about Promoting Anti-Wrinkle Drug before FDA Approval; Unbiased Information on Skin Care a Precious Resource Says SkinTour.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
(Date:1/15/2017)... CA (PRWEB) , ... January 15, 2017 , ... ... their choice of best physicians in eight Bay Area counties for 2017. Almost ... the healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/14/2017)... ... 2017 , ... Healthy living brand Moody Zook recently came ... With more and more people opting to go organic in their lifestyle, the ... to specific needs. , Moody Zook focused particularly on their newly launched activated ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... ... that raise blood sugar levels. Counting carbohydrates is as easy as checking the ... only nutrient that affects blood sugar levels. Despite being sugar-free, proteins can influence ...
(Date:1/13/2017)... ... January 13, 2017 , ... With ... on the challenge of providing additional organic alternatives for customers who have grown ... the brand’s new line of all-natural activated charcoal products, Moody Zook Chief Executive ...
Breaking Medicine News(10 mins):
(Date:1/12/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it has concluded agreements with the U.S. Department of ... (SEC) to resolve the previously disclosed U.S. Foreign Corrupt ... as in relation to the former deferred prosecution agreement ... with DOJ and SEC, respectively, on March 26, 2012.  ...
(Date:1/12/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... findings at this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) ... acnes -induced inflammation. The data will be shared ... Acne Pathogenesis," at ODAC, which is being held Jan. 13-16 ... ...
(Date:1/12/2017)... -- This new report from VPGMarketResearch contains 897 pages, ... German hospital microbiology testing market, including:  ... practice, as well as key economic, regulatory, demographic, social ... next ten years.  ... of major infectious diseases and microorganisms.  ...
Breaking Medicine Technology: